Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders

Rhea-AI Summary

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announced its participation at the International Congress of Parkinson's Disease and Movement Disorders in Madrid, Spain, from September 15-18, 2022. CEO Milton Werner, Ph.D., will present the abstract titled "IkT-148009 as a potential disease-modifying therapy in PD" during the GPT 6 session on September 16, 2022, from 1:00 – 3:00 p.m. CEST. Inhibikase focuses on developing therapies for Parkinson's disease and related disorders, with their lead program targeting the Abelson Tyrosine Kinase pathway to potentially modify the disease's course.

BOSTON and ATLANTA, Sept. 8, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that Milton Werner, Ph.D., President and Chief Executive Officer of Inhibikase, will present at the International Congress of Parkinson's Disease and Movement Disorders. The congress is being held in Madrid, Spain and virtually between September 15-18, 2022.

Presentation Details:

Abstract Title: IkT-148009 as a potential disease-modifying therapy in PD
Abstract Number: 789
Session: GPT 6, Parkinson's Disease: Clinical Trials
Presentation Date & Time: September 16, 2022, 1:00 – 3:00 p.m. CEST / 7:00 – 9:00a.m. EST
Location: France Gallery, Madrid Marriott Auditorium Hotel and Conference Center

About Inhibikase (www.inhibikase.com)
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Inhibikase's multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. Its multi-therapeutic pipeline is pursuing Parkinson's-related disorders of the brain and GI tract, orphan indications related to Parkinson's disease such as Multiple System Atrophy, and drug delivery technologies for kinase inhibitors such as IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate that the Company believes will provide a better patient experience with fewer on-dosing side-effects. The Company's RAMP™ medicinal chemistry program has identified a number of follow-on compounds to IkT-148009 to be potentially applied to other cognitive and motor function diseases of the brain. Inhibikase is headquartered in Atlanta, Georgia with offices in Boston, Massachusetts.

Social Media Disclaimer
Investors and others should note that the Company announces material financial information to investors using its investor relations website, press releases, SEC filings and public conference calls and webcasts. The Company intends to also use Twitter, Facebook, LinkedIn and YouTube as a means of disclosing information about the Company, its services and other matters and for complying with its disclosure obligations under Regulation FD.

Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as "believes," "expects," "may," "will," "should," "anticipates," "plans," or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Inhibikase's current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause Inhibikase's actual results to differ materially from those anticipated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in Inhibikase's filings with the SEC, including its annual report on Form 10-K for the year ended December 31, 2021, including under the caption "Risk Factors." Any forward-looking statement in this release speaks only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

Contacts:

Company Contact:
Milton H. Werner, Ph.D.
President & CEO
678-392-3419 
info@inhibikase.com

Investor Relations:
Alex Lobo
SternIR, Inc.
alex.lobo@sternir.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/inhibikase-therapeutics-to-present-at-the-international-congress-of-parkinsons-disease-and-movement-disorders-301615899.html

SOURCE Inhibikase Therapeutics, Inc.

FAQ

What is Inhibikase Therapeutics presenting at the International Congress?

Inhibikase Therapeutics is presenting the abstract titled "IkT-148009 as a potential disease-modifying therapy in PD" at the International Congress of Parkinson's Disease and Movement Disorders on September 16, 2022.

When is the presentation scheduled for Inhibikase Therapeutics?

The presentation by Inhibikase Therapeutics is scheduled for September 16, 2022, from 1:00 – 3:00 p.m. CEST.

Where is the International Congress of Parkinson's Disease and Movement Disorders taking place?

The International Congress is being held in Madrid, Spain, as well as virtually.

What is the focus of Inhibikase Therapeutics?

Inhibikase Therapeutics focuses on developing therapeutics for Parkinson's disease and related disorders, particularly targeting the Abelson Tyrosine Kinase pathways.

What is the stock symbol for Inhibikase Therapeutics?

The stock symbol for Inhibikase Therapeutics is IKT.